Morgan Stanley Maintains Overweight on Elevance Health, Raises Price Target to $585
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ha has maintained an Overweight rating on Elevance Health (NYSE:ELV) and raised the price target from $571 to $585.
July 25, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Elevance Health and raised the price target from $571 to $585, which could lead to a positive market reaction.
The raised price target by Morgan Stanley indicates a positive outlook for Elevance Health. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100